Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.MNLO · Entity 6871 | Chief Scientific Officer | December 11, 2019 | December 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date December 11, 2019 · Filed December 16, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 80,300 |
Reported balance
After 2019-12-11 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-12-11 · Exercise / conversion · Acquired 80,300 · Balance 80,300 F1: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. |
| Common StockSEC Table I · non-derivative | Direct | 52,534 |
Reported balance
After 2019-12-11 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2019-12-11 · Tax withholding · Disposed 27,766 · Balance 52,534 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-12-11 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2019-12-11 · Exercise / conversion · Disposed 80,300 · Balance 0 F1: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2019 Filed Dec 14, 2019 02:59 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon stock | 27,766 | $4.52 | $125,502.32 |
DisclosureSEC source: 0000899243-19-029192 · doc4.xml · nonDerivative · entry 2 Kwon Paul · CIK 0001727717 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,534 Read SEC document |
| December 11, 2019 Filed Dec 14, 2019 02:59 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon stock | 80,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029192 · doc4.xml · nonDerivative · entry 1 Kwon Paul · CIK 0001727717 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 22:13 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionRestricted Stock Units · Derivative | 80,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029291 · doc4a.xml · derivative · entry 3 Kwon Paul · CIK 0001727717 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.exercise_date: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.expiration_date: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 22:13 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 27,766 | $4.52 | $125,502.32 |
DisclosureSEC source: 0000899243-19-029291 · doc4a.xml · nonDerivative · entry 2 Kwon Paul · CIK 0001727717 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,534 Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 22:13 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon stock | 80,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029291 · doc4a.xml · nonDerivative · entry 1 Kwon Paul · CIK 0001727717 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:33 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantRestricted Stock Units · Derivative | 80,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-020701 · doc4.xml · derivative · entry 1 Kwon Paul · CIK 0001727717 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,812 Underlying: Common Stock · 80,300 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest in two (2) equal annual installments beginning July 29, 2020, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F3 · derivative.expiration_date: Not Applicable Read SEC document |
| July 29, 2019 Filed Aug 7, 2019 23:29 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantRestricted Stock Units · Derivative | 80,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-021298 · doc4a.xml · derivative · entry 1 Kwon Paul · CIK 0001727717 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,812 Underlying: Common Stock · 80,300 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest in two (2) equal annual installments beginning July 29, 2020, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissable Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F3 · derivative.expiration_date: Not Applicable Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:43 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001566044-18-000012 · edgardoc.xml · derivative · entry 1 Kwon Paul · CIK 0001727717 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. Read SEC document |
| May 03, 2018 Filed May 4, 2018 20:36 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001209191-18-028123 · doc4.xml · derivative · entry 1 Kwon Paul · CIK 0001727717 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,512 Underlying: Common Stock · 64,000 shares Expires 2028-05-02 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.